These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17491002)

  • 1. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
    Shahid M; Singhai M; Malik A; Shukla I; Khan HM; Shujatullah F; Tahira F
    J Antimicrob Chemother; 2007 Jul; 60(1):187-8. PubMed ID: 17491002
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE
    J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract]   [Full Text] [Related]  

  • 3. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
    Kuo HY; Wang FD; Yen YF; Lin ML; Liu CY
    New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
    Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
    J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
    Banic S
    APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Fujimura S; Takane H; Nakano Y; Watanabe A
    J Antimicrob Chemother; 2009 Nov; 64(5):1115-6. PubMed ID: 19744981
    [No Abstract]   [Full Text] [Related]  

  • 9. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of ceftriaxone plus tazobactam against members of Enterobacteriaceae.
    Prakash SK; Arora V; Prashad R; Sharma VK
    J Assoc Physicians India; 2005 Jul; 53():595-8. PubMed ID: 16190126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
    Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
    Liu Q; Rand K; Derendorf H
    Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-antibiotic and post-beta-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum beta-lactamase-producing Gram-negative bacteria.
    Lavigne JP; Bonnet R; Michaux-Charachon S; Jourdan J; Caillon J; Sotto A
    J Antimicrob Chemother; 2004 Apr; 53(4):616-9. PubMed ID: 14985275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
    Pultz MJ; Donskey CJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3044-5. PubMed ID: 17562802
    [No Abstract]   [Full Text] [Related]  

  • 18. [Characterization of the resistance to combinations of beta lactams and inhibitors of beta-lactamases in Escherichia coli. Effect of the type and amount of beta-lactamase production].
    del Mar Pérez-Moreno M; Pous-Miralles G; Romera-Sastre G; Panisello-Bertomeu JM; Jardí-Baiges AM; Zarazoga-López J
    Enferm Infecc Microbiol Clin; 1997 Nov; 15(9):477-81. PubMed ID: 9527373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid dissemination and diversity of CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America.
    Pallecchi L; Bartoloni A; Fiorelli C; Mantella A; Di Maggio T; Gamboa H; Gotuzzo E; Kronvall G; Paradisi F; Rossolini GM
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2720-5. PubMed ID: 17548490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Post antibiotic, post beta-lactamase inhibitor and post antibiotic sub-MIC effect of ceftriaxone/tazobactam on beta-lactamase-producing Escherichia coli in vitro].
    Zhang SC; Zhang LL; Chen SW; Wu HY; Liu XK
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Nov; 40(6):1071-4. PubMed ID: 20067122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.